These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1744714)

  • 21. Value of post-therapy whole-body I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose I-131 therapy.
    Spies WG; Wojtowicz CH; Spies SM; Shah AY; Zimmer AM
    Clin Nucl Med; 1989 Nov; 14(11):793-800. PubMed ID: 2513156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Value of posttherapeutic scintigraphy for the demonstration of distant metastases of differentiated carcinomas of the thyroid gland].
    Moser E; Hahn D; Wendt T; Büll U
    Strahlentherapie; 1983 Apr; 159(4):217-23. PubMed ID: 6857735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Role of the nuclear medicine in the treatment of thyroid carcinoma].
    Börner W; Reiners C
    Med Klin; 1980 Jan; 75(2):80-7. PubMed ID: 7374606
    [No Abstract]   [Full Text] [Related]  

  • 24. [The autonomous thyroid nodule: results of treatment with radioiodine].
    Schachter D; Atria A; Pineda G
    Rev Med Chil; 1986 Mar; 114(3):228-31. PubMed ID: 3544122
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of the therapeutic dose and diagnostic dose of 131I in the detection of metastatic foci of differentiated thyroid cancer.
    Tung CC; Chang TC; Su CT; Chen FW; Chang CC
    Taiwan Yi Xue Hui Za Zhi; 1988 Nov; 87(11):1081-5. PubMed ID: 3235967
    [No Abstract]   [Full Text] [Related]  

  • 26. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131.
    Park HM; Perkins OW; Edmondson JW; Schnute RB; Manatunga A
    Thyroid; 1994; 4(1):49-54. PubMed ID: 8054861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bone marrow changes in patients with thyroid carcinoma].
    Linden A; Weiss R; Smolarz K; Jungehülsing M; Theissen P; Schicha H
    Nuklearmedizin; 1991 Dec; 30(6):272-8. PubMed ID: 1780240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scanning dose and detection of thyroid metastases.
    Coakley AJ; Page CJ; Croft D
    J Nucl Med; 1980 Aug; 21(8):803-4. PubMed ID: 6772746
    [No Abstract]   [Full Text] [Related]  

  • 29. Scintigraphy and treatment of medullary carcinoma of the thyroid with iodine-131 metaiodobenzylguanidine.
    Clarke SE; Lazarus CR; Edwards S; Murby B; Clarke DG; Roden TM; Fogelman I; Maisey MN
    J Nucl Med; 1987 Dec; 28(12):1820-5. PubMed ID: 3681441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioiodine ablation outcomes after imaging with 123I or 131I: is no news good news?
    Burniston MT; Wilson DJ
    J Nucl Med; 2008 Jan; 49(1):166; author reply 166-7. PubMed ID: 18165699
    [No Abstract]   [Full Text] [Related]  

  • 31. Whole body scintigram with 131I before and immediately after the ablation or tumor dose in patients with differentiated thyroid carcinoma and the effect of endogenous stimulation of thyrostimulating hormone on thyroglobulin in same patients.
    Malesevic M; Stefanovic L; Popovic S; Prvulovic M; Selir Z; Milkovic L
    Radiobiol Radiother (Berl); 1987; 28(5):651-3. PubMed ID: 3441615
    [No Abstract]   [Full Text] [Related]  

  • 32. Spurious thyroid cancer metastasis: saliva contamination artifact in high dose iodine-131 metastases survey.
    Park HM; Tarver RD; Schauwecker DS; Burt R
    J Nucl Med; 1986 May; 27(5):634-6. PubMed ID: 3712080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of thallium-201 total-body scintigraphy in follow-up of thyroid carcinoma.
    Hoefnagel CA; Delprat CC; Marcuse HR; de Vijlder JJ
    J Nucl Med; 1986 Dec; 27(12):1854-7. PubMed ID: 3097277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Metastatic differentiated thyroid cancer. Diagnostic accuracy of thyroglobulin-RIA in comparison with 131I-whole body scintigraphy].
    Reiners C; Reimann J; Schäffer R; Baum K; Becker W; Eilles C; Gerhards W; Schick F; Spiegel W; Wiedemann W
    Rofo; 1984 Sep; 141(3):306-13. PubMed ID: 6435198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole-body thyroid tumor 123I scintigraphy.
    Gerard SK
    J Nucl Med; 2003 May; 44(5):852. PubMed ID: 12732689
    [No Abstract]   [Full Text] [Related]  

  • 36. [The use of 131I in the combined modality therapy of highly differentiated cancer of the thyroid gland].
    Baranauskas ZL; Mamontov VV; Valutskas KK
    Med Radiol (Mosk); 1989 Oct; 34(10):31-4. PubMed ID: 2811625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical value of serum thyroglobulin and 131I-whole body retention measurements in the diagnosis of metastases from differentiated thyroid carcinoma (author's transl)].
    Weissel M; Bergmann H; Höfer R
    Acta Med Austriaca; 1980; 7(4-5):114-9. PubMed ID: 7246011
    [No Abstract]   [Full Text] [Related]  

  • 38. Practical dosimetry of 131I in patients with thyroid carcinoma.
    Sisson JC
    Cancer Biother Radiopharm; 2002 Feb; 17(1):101-5. PubMed ID: 11915166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complementary role of whole body scan and serum thyroglobulin determination in the follow-up of differentiated thyroid carcinoma.
    Ronga G; Fiorentino A; Fragasso G; Fringuelli FM; Todino V
    Ital J Surg Sci; 1986; 16(1):11-5. PubMed ID: 3087907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The case for obtaining a diagnostic whole-body scan prior to iodine 131 treatment of differentiated thyroid cancer.
    McDougall IR
    Thyroid; 2009 Aug; 19(8):811-3. PubMed ID: 19645613
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.